Peripheral CXCR3‐Associated Chemokines as Biomarkers of Fibrosis in Chronic Hepatitis C Virus Infection

Zeremski, Marija; Dimova, Rositsa B.; Brown, Queenie B.; Jacobson, Ira M.; Markatou, Marianthi; Talal, Andrew H.

doi:10.1086/646614

Cited by 104 publications

(107 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comparing F2 and F4 patients the concentrations of IL-2R, IL-6, IL-8, CXCL9, CXCL10, CXCL12 and MIF were found statistically higher (with p<0.05) in chronic inflammation patients with F4 fibrosis grade in respect to F2 fibrosis grade . These data agreed with a recent paper reporting that CXCL9 and CXCL10 were significantly elevated in patients with advanced fibrosis (Zeremski et al 2009). …”

Section: Chronic Inflammation Patients With Different Fibrosis Stagessupporting

confidence: 93%

The Value of the Cytokinome Profile

Costantini¹,

Sharma²,

Colonna³

2011

Inflammatory Diseases - A Modern Perspective

View full text Add to dashboard Cite

Section: Chronic Inflammation Patients With Different Fibrosis Stagessupporting

confidence: 93%

The Value of the Cytokinome Profile

Costantini¹,

Sharma²,

Colonna³

2011

Inflammatory Diseases - A Modern Perspective

View full text Add to dashboard Cite

“…3 More than 50% of HCV cases remain asymptomatic in the initial phase, and are not diagnosed prior to onset of severe hepatic fibrosis. 4 HCV is therefore the leading cause of liver transplants in Europe and America. 3,5 Early detection of HCV and appropriate therapeutic management in chronic patients can prevent these complications and therefore improve patient health and reduce patient morbidity and mortality.…”

Section: Introductionmentioning

confidence: 99%

Diagnosis and Management of Hepatitis C Virus Infection

et al. 2015

View full text Add to dashboard Cite

The hepatitis C virus (HCV) infects more than 200 million people globally, with increasing incidence, especially in developing countries. HCV infection frequently progresses to chronic liver disease, creating a heavy economic burden on resourcepoor countries and lowering patient quality of life. Effective HCV diagnosis, treatment selection, and treatment monitoring are important in stopping disease progression. Serological assays, which detect anti-HCV antibodies in the patient after seroconversion, are used for initial HCV diagnosis. Qualitative and quantitative molecular assays are used to confirm initial diagnosis, determine viral load, and genotype the dominant strain. Viral load and genotype information are used to guide appropriate treatment. Various other biomarker assays are performed to assess liver function and enable disease staging. Most of these diagnostic methods are mature and routinely used in high-resource countries with well-developed laboratory infrastructure. Few technologies, however, are available that address the needs of low-resource areas with high HCV prevalence, such as Africa and Southeast Asia.

show abstract

“…Pro-inflammatory cytokines and chemokines are involved in this process and plasma levels of these may be associated with different stages of hepatitis C associated liver fibrosis [9;10]. Although current knowledge about these inflammatory cytokines and chemokines is limited, studies have demonstrated that plasma levels of some chemokines correlate with liver fibrosis [11][12][13]. There is a need for non-invasive, simple, inexpensive and accurate tools to determine and monitor liver fibrosis in CHC patients.…”

Section: Introductionmentioning

confidence: 99%